197 related articles for article (PubMed ID: 750275)
1. Antitumor activity of prolonged-release derivative of cytosine arabinoside, cytosine arabinoside-agarose conjugate.
Hashida M; Kojima T; Muranishi S; Sezaki H
Gan; 1978 Dec; 69(6):839-43. PubMed ID: 750275
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
Avramis VI; Powell W
Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugated with polyglutamic acid and its derivative.
Kato Y; Saito M; Fukushima H; Takeda Y; Hara T
Cancer Res; 1984 Jan; 44(1):25-30. PubMed ID: 6197162
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of 5'-esters of 1-beta-D-arabinofuranosylcytosine.
Ho DH; Neil GL
Cancer Res; 1977 Jun; 37(6):1640-3. PubMed ID: 870178
[TBL] [Abstract][Full Text] [Related]
5. [Experimental study on the correlation between the antitumor activity and pharmacokinetics of cytosine arabinoside (Ara-C) and N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC)].
Takenaka T; Kimura K
Nihon Gan Chiryo Gakkai Shi; 1985 Dec; 20(10):2322-8. PubMed ID: 3831176
[No Abstract] [Full Text] [Related]
6. Antitumor effects and pharmacology of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in mice.
Hori K; Tsuruo T; Naganuma K; Tsukagoshi S; Sakurai Y
Cancer Res; 1984 Jan; 44(1):172-7. PubMed ID: 6690034
[TBL] [Abstract][Full Text] [Related]
7. [Studies on the relationship between therapeutic schedule and antitumor effect of etoposide and cytosine arabinoside in murine L1210 leukemia].
Ooi K; Ohkubo T; Kawasaki H; Sakurai M
Yakugaku Zasshi; 1989 Nov; 109(11):865-8. PubMed ID: 2614669
[TBL] [Abstract][Full Text] [Related]
8. Formulation, stability, and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugate of thioether phospholipid.
Hong CI; Bernacki RJ; Hui SW; Rustum Y; West CR
Cancer Res; 1990 Jul; 50(14):4401-6. PubMed ID: 2364392
[TBL] [Abstract][Full Text] [Related]
9. Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes.
Rubas W; Supersaxo A; Weder HG; Hartmann HR; Hengartner H; Schott H; Schwendener R
Int J Cancer; 1986 Jan; 37(1):149-54. PubMed ID: 3941019
[TBL] [Abstract][Full Text] [Related]
10. Conjugate of N4-(4-carboxybutyryl)-ara-C and ethylenediamine-introduced dextran. Drug release profiles and further in vivo study of its antitumor effects.
Onishi H; Seno Y; Pithayanukul P; Nagai T
Drug Des Deliv; 1991 Apr; 7(2):139-45. PubMed ID: 1716902
[TBL] [Abstract][Full Text] [Related]
11. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine.
Li ZR; Campbell J; Rustum YM
Cancer Treat Rep; 1983 Jun; 67(6):547-54. PubMed ID: 6190558
[TBL] [Abstract][Full Text] [Related]
12. Modulation of cytosine arabinoside toxicity by 3-deazauridine in a murine leukemia model.
Grem JL; Plowman J; Rubinstein L; Hawkins MJ; Harrison SD
Leuk Res; 1991; 15(4):229-36. PubMed ID: 2030604
[TBL] [Abstract][Full Text] [Related]
13. Paradoxical effect of cytosine arabinoside on mouse leukemia cell line L1210 cells.
Nakayama T; Sakamoto S; Sassa S; Suzuki S; Kudo H; Nagasawa H
Anticancer Res; 2005; 25(1A):157-60. PubMed ID: 15816533
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of synergistic cell killing when methotrexate precedes cytosine arabinoside: study of L1210 and human leukemic cells.
Cadman E; Eiferman F
J Clin Invest; 1979 Sep; 64(3):788-97. PubMed ID: 288743
[TBL] [Abstract][Full Text] [Related]
15. Phospholipid derivatives of nucleoside analogs as prodrugs with enhanced catabolic stability.
Matsushita T; Ryu EK; Hong CI; MacCoss M
Cancer Res; 1981 Jul; 41(7):2707-13. PubMed ID: 7248939
[TBL] [Abstract][Full Text] [Related]
16. Response of lymphoid leukemia L1210 in mice to implantable sustained release cytosine arabinoside capsules.
Fu JC; Khwaja T; Moyer DL; Cummings L; Varvan J; Elshire D
J Surg Oncol; 1978; 10(1):1-7. PubMed ID: 628213
[TBL] [Abstract][Full Text] [Related]
17. [Influencing factors in the leakage of liposome and arabinoside cytosine (ARA-C) entrapped in liposomes in treatment of L1210 mouse leukemia].
Fu NW
Zhonghua Zhong Liu Za Zhi; 1985 Jul; 7(4):250-3. PubMed ID: 4085312
[TBL] [Abstract][Full Text] [Related]
18. Studies of the L1210 antileukemic activity of O-2,2'-cyclocytidine, monoacetate (anhydro-ara-C; NSC-129220)--comparison with cytosine arabinoside (NSC-63878) with respect to treatment schedule dependency.
Venditti JM; Baratta MC; Greenberg NH; Abbott BJ; Kline I
Cancer Chemother Rep; 1972 Aug; 56(4):483-92. PubMed ID: 5081591
[No Abstract] [Full Text] [Related]
19. [Selective treatment of leukemia L1210 with combination of deoxycytidine and lethal doses of cytosine arabinoside].
Bukhman VM; Lichinitser MR; Svet-Moldavskiĭ GIa; Mkheidze DM
Biull Eksp Biol Med; 1978 Mar; 85(3):340-3. PubMed ID: 276385
[TBL] [Abstract][Full Text] [Related]
20. [Antitumor activity of a novel analog of cytarabine, 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone 5'-(sodium octadecyl phosphate) monohydrate (YNK01)].
Nagahata T; Shibasaki C; Ishii T; Uchida T; Arakawa M; Kusama K; Ekimoto H; Takahashi K
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1437-45. PubMed ID: 2389942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
